Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

May 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-05-11

Reporting Person: Martin Michael Robert (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-11	Common Stock	M	20000	$3.02	Acquired	221861	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-11	Option Grant (right to buy)	$3.02	M	20000	Disposed	2021-03-30	Common Stock (20000.0)	Direct

Footnotes

F1: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F2: The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date. The expiration date was extended as a result of the blackout period.